Remove 2004 Remove Clinical Trials Remove Consumption Remove THC
article thumbnail

Using Cannabis for ALS: Benefits, Research and Best Strains

Greencamp

This is how the psychoactive intoxication with THC affects our brain, and this same pathway is activated for the many other medical benefits cannabis has to offer. Also presented in the American Journal of Hospice and Palliative Care, a 2004 survey set about to discover the effect of cannabis use on ALS in humans.

Strains 94
article thumbnail

Best strains and terpenes for migraine relief

The Cannigma

Based on the limited existing evidence, the best cannabis strain for migraines may be a Type II that includes both THC and CBD, and a terpene profile that includes beta-caryophyllene, myrcene, linalool, limonene, bisabolol, humulene or pinene. 5 THC and migraines THC is well-known for its anti-nausea and pain-relieving effects.

Terpenes 132
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). The TGA regulations permit applications for most cannabis products but nevertheless distinguish between cannabis products based on CBD and THC. 2016 ; Sznitman et al.

article thumbnail

ElleVet Sciences Publishes Safety Study On CBD For Animals

Cannabis Law Report

Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinical trial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement.

Safety 45
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.